

**ProteoTech's Chief Scientific Officer, Dr. Alan Snow, to speak at
the 5th Drug Discovery for Neurodegeneration Conference:
San Diego, CA, February 6-8, 2011**

ProteoTech, Inc., February 3, 2011 announced that the Company's President and Chief Scientific Officer, Alan D. Snow, Ph.D., was an invited speaker at the 5th Drug Discovery for Neurodegeneration Conference, February 6-8 in San Diego, CA. Dr. Snow's talk was entitled:

“Novel Ways to Reduce Protein Aggregation”

The talk highlighted ProteoTech's small molecule platform technology to develop disease-modifying drugs for amyloid diseases including Parkinson's, Alzheimer's, Systemic AA Amyloidosis, and Type 2 Diabetes diseases.

About ProteoTech: ProteoTech is a private drug development company located in the Seattle, WA area (Kirkland, WA), and is focused on targeting amyloid diseases. The Company is developing *Synuclein*[™] for the treatment of Parkinson's disease, EXEBRYL[®] for the treatment of Alzheimer's disease, Systebryl[™] for the treatment of Systemic Amyloidosis, and is in late stage pre-clinical development for a novel small peptide called *PeptiClere*[™] for the treatment of Alzheimer's disease. For more information please see the Company web site at www.proteotech.com.